Apache Corporation Named One of the World's Most Admired Companies by Fortune
HOUSTON, Jan. 22, 2019 (GLOBE NEWSWIRE) — Apache Corporation (NYSE, Nasdaq: APA) has been named by FORTUNE magazine as one […]
Voyager Therapeutics Appoints Robert Hesslein as General Counsel
CAMBRIDGE, Mass., Jan. 22, 2019 (GLOBE NEWSWIRE) — Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on […]
Patient-Level Survival Analysis Demonstrates No Link Between Paclitaxel Dose and Mortality in Patients Treated with IN.PACT Admiral DCB
Data Presented Today at LINC Reiterate Commitment to Patient Safety and Data Transparency DUBLIN and LEIPZIG, Germany – January 22, […]
Research Finds Gender “Enthusiasm Gaps” in the Workplace
New Research Analysis by FTI Consulting and Mine The Gap Highlights Differences in […]
Mechel Completes Restructuring Syndicated Pre-Export Loan
MOSCOW, Jan. 22, 2019 (GLOBE NEWSWIRE) — Mechel PAO (MOEX: MTLR; NYSE: MTL), a leading Russian mining and metals company, […]
uniQure Announces FDA Clearance of Investigational New Drug Application for AMT-130 in Huntington’s Disease
~ AMT-130 Poised to Become First AAV Gene Therapy to Enter the Clinic for Huntington’s Disease ~ ~ Lead Product […]
LGI Homes Adds Townhomes to Its Crystal Lakes Community Near Katy
BROOKSHIRE, Texas, Jan. 22, 2019 (GLOBE NEWSWIRE) — LGI Homes, Inc. (Nasdaq:LGIH) today announced the construction of a new section […]
Capricor Announces Positive Outcomes from Comprehensive Multidisciplinary Meeting with FDA
FDA Provides Positive Feedback on Design for HOPE-2 Clinical Trial LOS ANGELES, Jan. 22, 2019 (GLOBE NEWSWIRE) — Capricor Therapeutics […]
CRISPR Therapeutics and ProBioGen Sign Collaboration and License Agreement to Develop Novel In Vivo Delivery Technologies
CAMBRIDGE, Mass. and BOSTON and BERLIN, Jan. 22, 2019 (GLOBE NEWSWIRE) — CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating […]
Sorrento Therapeutics Announces Interim Results In Osteoarthritis Knee Pain Phase 1b Trial of Resiniferatoxin With Positive Therapeutic Signal and Absence of Dose Limiting Toxicities; Pivotal Trials Targeted to Start Later 2019
SAN DIEGO, Jan. 22, 2019 (GLOBE NEWSWIRE) — Sorrento Therapeutics, Inc. (NASDAQ: SRNE, “Sorrento”) announced that the phase 1b study […]
